Laborie Medical Technologies announced today that it completed the acquisition of drug-coated balloon developer Urotronic. The companies struck an agreement last month for Laborie to buy Urotronic for up to $600 million. Urotronic developed the Optilume DCB used in interventional urology procedures. It treats urethral strictures and benign prostatic hyperplasia (BPH) or enlarged prostate conditions. […]
Catheters
Boston Scientific shares positive drug-coated balloon data
Boston Scientific announced positive data from a trial of its Agent drug-coated balloon (DCB). The Marlborough, Massachusetts-based company presented its results at the Transcatheter Cardiovascular Therapeutics (TCT) meeting. Data demonstrated statistical superiority for Agent compared to uncoated balloon angioplasty. AGENT IDE evaluated the safety and effectiveness of using a DCB to treat coronary in-stent restenosis […]
Integer scores a big Q3 earnings beat, closes tuck-in acquisition
Medtech contract manufacturing giant Integer saw its stock jump more than 14% in value today on Street-beating third-quarter earnings and upped guidance. Plano, Texas–based Integer also announced that it has spent $42 million to acquire certain assets of InNeuroCo to boost its neurovascular catheter capabilities. The deal, which closed Oct. 1, will add $5 million […]
The biggest cardiovascular stories from TCT 2023
Every year, some of the biggest names in cardiovascular technologies come together in one place for TCT. This year’s 35th edition of the Transcatheter Cardiovascular Therapeutics annual scientific symposium was no different in San Francisco. Usual suspects like Medtronic and Abbott released data covering a range of products, while other big names like Edwards, GE […]
Edwards Lifesciences says TAVR drove 12% sales growth in Q3
Edwards Lifesciences reported third-quarter results that met Wall Street expectations, with solid sales growth keeping it on track to boost revenue by up to 13% this year. Investors may have expected more from the maker of catheter-delivered heart implants, including transcatheter aortic valve replacement systems and transcatheter mitral and tricuspid therapies. The morning after the […]
Slow and steady wins the race: JenaValve aims to offer new option for aortic regurgitation patients
The Munich-based startup JenaValve is a bit like the tortoise, with a slow and steady approach to transcatheter aortic valve replacement (TAVR) device development. At the Transcatheter Cardiovascular Therapeutics (TCT) conference today, Dr. Vinod Thourani, co-principal investigator of the ALIGN-AR study, jokingly compared the company’s approach to a “nice bottle of wine” that gets better […]
Shockwave Medical launches new coronary IVL catheter following FDA approval
Shockwave Medical announced today that it unveiled a new coronary intravascular lithotripsy (IVL) catheter in the U.S. The planned introduction of the Shockwave C2+ coronary IVL catheter follows the receipt of FDA approval. This catheter offers 50% more pulses per catheter than the Shockwave C2 catheter that the FDA approved in June 2021. Santa Clara, California-based […]
FDA clears Cardio Flow’s FreedomFlow orbital atherectomy peripheral platform
Cardio Flow this week received FDA 510(k) clearance for its FreedomFlow orbital atherectomy peripheral platform. The St. Paul, Minnesota-based company designed FreedomFlow with a modern mechanism of action to clear plaque blockages in the arteries of the legs. The catheter-based design uses the physics of angular momentum, creating a spiral geometry that puts five diamond-coated […]
Intravascular ultrasound tech developer Evident Vascular exits stealth mode with $35M Series A
Intravascular ultrasound startup Evident Vascular announced today that it launched with a $35 million Series A financing round. San Jose, California-based Evident Vascular develops an IVUS platform leveraging artificial intelligence (AI). It enables both superior imaging and streamlined workflows. The company’s launch came with the $35 million in funding from Vensana Capital. Managing Partner Dr. […]
FDA issues warning letter to J&J’s Abiomed over Impella heart pump problems
Abiomed, a Johnson & Johnson unit, has received an FDA warning letter related to its Class I recall of Impella heart pumps. The agency wrote Abiomed up for failing to report problems with the heart pump and selling its Impella Connect System software and hardware without FDA authorization. The FDA issued the letter in September after inspecting […]
Teleflex completes Palette Life Sciences acquisition
Teleflex (NYSE: TFX) this week completed the previously announced acquisition of Palette Life Sciences. The Wayne, Pennsylvania-based company first announced the acquisition in July. Under the terms of the agreement, Teleflex bought Palette for an upfront cash payment of $600 million at closing, with additional consideration of up to $50 million upon the achievement of […]